Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and Tissue Data Confirm NaviCap Platform Delivers Topically Through the Entire Colon, With Lower Systemic Concentrations, as Desired'
Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and Tissue Data Confirm NaviCap Platform Delivers Topically Through the Entire Colon, With Lower Systemic Concentrations, as Desired'
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.